ArticleInternational journal of molecular medicine2018
Protective effect of luteolin on skin ischemia-reperfusion injury through an AKT-dependent mechanism.
Article in International journal of molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Trial
- A translational mechanistic synthesis of ischemia-reperfusion injury in experimental flap models toward free flap salvage.Frontiers in surgery · 2026Review
- Targeting Programmed Cell Death in Flap Ischemia/Reperfusion Injury.Biomolecules · 2025Review
- Luteolin ameliorates ischemic/reperfusion injury by inhibiting ferroptosis.Metabolic brain disease · 2025Article
- Emerging therapeutic strategies: The potential of caffeic acid-vanadium nanozymes in modulating macrophage function and reducing skin flap ischemia-reperfusion injury.Acta pharmaceutica Sinica. B · 2025Article
- Unlocking the potential of luteolin: A natural migraine management approach through network pharmacology.Journal of traditional and complementary medicine · 2024Article
- Protective effects of the bioactive peptide from maggots against skin flap ischemia‒reperfusion injury in rats.Heliyon · 2024Article
- Healing Effects of Luteolin Versus Silver Sulphadiazine on Second-Degree Burn Wounds in Animal Model.Galen medical journal · 2024Article
- Improving the ischemia-reperfusion injury in vascularized composite allotransplantation: Clinical experience and experimental implications.Frontiers in immunology · 2022Review
- Tissue-Protective Mechanisms of Bioactive Phytochemicals in Flap Surgery.Frontiers in pharmacology · 2022Review
- Luteolin Attenuates Cognitive Dysfunction Induced By Chronic Cerebral Hypoperfusion Through the Modulation of The PI3K/Akt Pathway in Rats.Journal of veterinary research · 2021Article
- GRK2 deletion improves the function of skin flap following ischemia-reperfusion injury by regulating Drp1.American journal of translational research · 2021Article
- Positive Effect of Andrographolide Induced Autophagy on Random-Pattern Skin Flaps Survival.Frontiers in pharmacology · 2021Article
- Network Pharmacology Identifies the Mechanisms of Action of TaohongSiwu Decoction Against Essential Hypertension.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- D-allose alleviates ischemia/reperfusion (I/R) injury in skin flap via MKP-1.Molecular medicine (Cambridge, Mass.) · 2020Article
- Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin.BioMed research international · 2020Article
- Butylphthalide Inhibits Autophagy and Promotes Multiterritory Perforator Flap Survival.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous ischemia‑reperfusion (I/R) injury is one of the most crucial problems in flap surgery, which affects the survival of the skin flap and patient prognosis, luteolin, a plant derived flavonoid, has previously been shown to exert a variety of beneficial effects for reducing I/R injury in several organs. The aim of the present study was to evaluate the anti‑inflammatory and anti‑oxidative stress effects of luteolin on cutaneous I/R injury. The in vitro study were performed using a permanent human immortalized epidermal keratinocyte cell line (HaCaT), cells were cultured in the presence of luteolin and were then treated with hydrogen peroxide, the cell viability, mitochondrial membrane potential and the cell survival/apoptosis related signaling pathway activation were assessed to investigate the cytoprotective effects of luteolin. For in vivo experiments, skin flap I/R injury animal model was established in Sprague‑Dawley rats, by measuring the area of flap survival, analyzing the expression of pro‑inflammatory cytokine and evaluation of the histological changes in the skin tissue, the protective effects of luteolin on skin I/R injury were investigated. The function of protein kinase B (AKT) and heme oxygenase‑1 (HO‑1) activation on luteolin mediated I/R injury protection was assessed by administration of phosphoinositide‑3‑kinase/AKT inhibitor LY294002 and HO‑1 inhibitor ZNPP. The results showed that luteolin treatment significantly increased the viability of HaCaT cells upon exposure to hydrogen peroxide, and the administration of luteolin in vivo significantly improved skin flap survival in the I/R injury rat model. The mechanisms underlying these beneficial effects included increased phosphoinositide‑3‑kinase/protein kinase B activation, improved expression of antioxidant enzyme, and scavenging the cytotoxic effects of reactive oxygen species (ROS). Taken together, the results suggested that luteolin preconditioning yielded significant protection against cutaneous I/R injury by protecting skin keratinocytes from ROS‑induced damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.